Brief: Basilea: Continued Strong Cresemba Sales By Astellas In U.S. Trigger CHF 20 Mln Sales Milestone Payment To Basilea

Basilea Pharmaceutica AG, Allschwil

09/01/2023 06:19

Jan 9 (Reuters) - Basilea Pharmaceutica AG  BSLN.S :
    * CONTINUED STRONG CRESEMBA® (ISAVUCONAZOLE) SALES BY
ASTELLAS IN
THE U.S. TRIGGER CHF 20 MILLION SALES MILESTONE PAYMENT TO
BASILEA
    * BASILEA IS ENTITLED TO RECEIVE MILESTONE PAYMENTS BASED ON
ASTELLAS EXCEEDING CERTAIN NET SALES THRESHOLDS IN UNITED STATES
WITHIN A CALENDAR YEAR
    * TOTAL SALES MILESTONE PAYMENTS FROM ASTELLAS TO DATE
AMOUNT TO
CHF 50 MILLION, INCLUDING CHF 20 MILLION TRIGGERED NOW
    * BASILEA IS ELIGIBLE FOR ADDITIONAL SALES MILESTONE
PAYMENTS OF
UP TO CHF 240 MILLION, IN ADDITION TO TIERED, DOUBLE-DIGIT
ROYALTIES ON U.S. NET SALES

Further company coverage:  BSLN.S 
 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))